Phase 2 third cohort (28 days, 15 mg) generally safe and well toleratedARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026Cash runway extended into Q2 2028Investor ...
Arcturus Therapeutics (NASDAQ: ARCT) is gearing up to announce its quarterly earnings on Tuesday, 2026-03-03. Here's a quick ...
We recently published an article titled 11 High Growth Micro-cap Stocks to Buy. On January 6, Citi lowered its price target on Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) to $7 from $9 while ...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease ...
In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis (CF). The findings, shared today before market open, ...
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class I CF participants exhibited encouraging reduction of mucus plug number and mucus volume 12-week study enrolling up to 20 CF ...
AbbVie, Capstan Therapeutics and other defendants were hit with a trade secret lawsuit on Sept. 23 in California Southern District Court. The suit, filed by Wilson Sonsini Goodrich & Rosati on behalf ...
Sept 23 (Reuters) - Biotech company Arcturus Therapeutics (ARCT.O), opens new tab sued AbbVie (ABBV.N), opens new tab in California federal court on Tuesday for allegedly stealing trade secrets ...
Biotech company Arcturus Therapeutics sued AbbVie in California federal court on Tuesday for allegedly stealing trade secrets related to its drug-delivery technology. Reuters, the news and media ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2025 Earnings Call Transcript August 11, 2025 Arcturus Therapeutics Holdings Inc. beats earnings expectations. Reported EPS is $-0.34, expectations ...
Arcturus Therapeutics believes it’s “highly unlikely” it will lose the promised government funding for its bird flu mRNA vaccine trial, despite reports swirling that Moderna’s own financial support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results